Kyowa Kirin continues to investigate the root cause of quality defect in a batch of Bleo-Medac Powder for Solution for Injection, 15,000 IU - reports of glass particles, which resulted in recall in some European countries. No recall action was necessary in the UK as the affected batch had not been distributed in the UK. To maintain continuity of supply in the UK, the marketing authorisation holder will distribute new batches of Bleo-Kyowa that meet current specifications. However, while investigations continue, the MHRA recommends that healthcare professionals adopt precautionary measures during product reconstitution.